Alexandria Real Estate Equities buys LIC building for $75M

Brickman Real Estate and Daniel Loeb’s Third Point are the sellers of The Bindery at 30-03 48th Avenue

New York /
Oct.October 10, 2018 08:25 AM

Alexandria Real Estate Equities’ Joel Marcus and 30-02 48th Avenue (Credit: Startup Columbia and Google Maps)

Alexandria Real Estate Equities, which expanded its footprint in New York City earlier this year with the purchase of Pfizer’s headquarters in Manhattan, is bringing one of its life-science centers to Long Island City.

The California-based real estate investment trust bought The Bindery building at 30-02 48th Avenue from a partnership led by Brickman Real Estate for $75 million, sources told The Real Deal.

The purchase of the 175,000-square-foot property closed yesterday at a value of $430 per square foot. Representatives for Alexandria and Brickman could not be immediately reached for comment.

A Cushman & Wakefield team led by Josh King, Adam Spies and Doug Harmon represented Brickman in the sale. The brokers were unavailable for comment.

From left: Josh King, Adam Spies and Doug Harmon

Alexandria specializes in developing offices and lab space for science and technology tenants, a high-growth industry that is filling millions of square feet in places like Boston, and is in its nascent stages here in New York.

The developer opened its Alexandria Center for Life Science biotech incubator in Midtown East in 2010, and plans to convert the Bindery building for similar uses.

The three-story former warehouse, dating back to 1926, sits just a few steps away from other successful industrial-to-office conversions such as the 1 million-square-foot Factory building that Atlas Capital Group recapitalized earlier this year at a value of $400 million – or $400 per square foot – and The Falchi building, which Savanna Real Estate bought in 2016 for $257.5 million – or just shy of $400 per square foot.

Fifth Avenue-based Brickman bought The Bindery building in 2013 for $21 million, and in 2016 the investment firm brought in hedge funder Daniel Loeb’s Third Point Management in as a partner to buy a 90 percent stake in the property for just over $24 million. The Cushman brokers negotiated that deal while at Eastdil Secured.

The investors pumped more than $20 million into upgrading the property.

Alexandria, meanwhile, bought Pfizer’s headquarters at 219 East 42nd Street earlier this year for $360 million with investor David Werner, a deal in which the Cushman team negotiated the sale.

The owners plan to convert the property for life-science tenants in five years when Pfizer vacates the building and relocates to Hudson Yards.

Hiten Samtani contributed reporting.


Related Articles

arrow_forward_ios
(Moinian Group, CVS)
CVS signs lease for 512 7th Avenue store
CVS signs lease for 512 7th Avenue store
U.S. President Joe Biden removes his mask before speaking about updated CDC mask guidance. (Getty)
In CDC we trust: Mask guidance prompts changes
In CDC we trust: Mask guidance prompts changes
Major real estate stocks ended in negative territory this week. (Getty)
Real estate stocks, markets jittery over inflation
Real estate stocks, markets jittery over inflation
Joseph Chetrit with 427 and 459 (left) Broadway (Getty, Beyond My Ken/Wikimedia)
Chetrit Group falls behind on Soho portfolio mortgage
Chetrit Group falls behind on Soho portfolio mortgage
Joel Landau, chairman and founder of Allure Group. (Google Maps, Score NYC)
These were the top outer-borough loans last month
These were the top outer-borough loans last month
David Schonbraun (SL Green)
SL Green investment chief David Schonbraun steps down
SL Green investment chief David Schonbraun steps down
Aby Rosen and 522 Fifth Avenue (Getty, Google Maps)
RFR pitches Fifth Avenue office building as “build-to-suit” corporate HQ
RFR pitches Fifth Avenue office building as “build-to-suit” corporate HQ
Nearly half of new shops in 2021 will be dollar stores. (Getty)
2021 is raining dollar stores
2021 is raining dollar stores
arrow_forward_ios

The Deal's newsletters give you the latest scoops, fresh headlines, marketing data, and things to know within the industry.

Loading...